{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:12:29Z","timestamp":1697368349813},"reference-count":11,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2007,11,2]],"date-time":"2007-11-02T00:00:00Z","timestamp":1193961600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:p>A 40\u2010year\u2010old man was referred to our department in January 2000 with persistent, scaly, pustular and tender plaques on the distal portion of the digits. He first noted pustulation around the nail, which was followed by scaling and crust formation, and subsequently led to nail dystrophy. Earlier treatment had included topical antibiotics, antimycotics, and corticosteroids, as well as systemic antibiotics, without any success. His past medical history was otherwise unremarkable. Post\u2010traumatic fingertip amputation of the third finger of the right hand was repaired with a full\u2010thickness skin graft. On dermatologic examination, there was a severe erythematosquamous, psoriasiform, pustular eruption surrounded by a hyperemic area affecting the terminal phalanges of nine of the 10 digits. The skin of the graft was intact. Examination of the digits revealed anonychia of six of the 10 fingernails (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#f1\">Fig.\u00a01<\/jats:ext-link>) The rest of the physical examination was normal. Clinical and histologic findings led to the diagnosis of acrodermatitis continua of Hallopeau (ACH). X\u2010Rays of both hands showed osteolysis of two of the 10 terminal phalanges.<\/jats:p><jats:p><jats:fig><jats:caption><jats:p>Before therapy: acrodermatitis continua of Hallopeau demonstrating acral pustule formation<\/jats:p><\/jats:caption><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" position=\"anchor\" xlink:href=\"urn:x-wiley:00119059:media:IJD3251:IJD_3251_f1\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:fig><\/jats:p><jats:p>Initial therapy was with acitretin (up to 1\u00a0mg\/kg). This treatment produced moderate clinical improvement, but was discontinued after 4\u00a0months because of a sudden increase in serum lipids. Treatment with topical corticosteroids under occlusion, combined with psoralen plus ultraviolet A (PUVA) twice weekly, was started, but this gave only a slight improvement. Over the following 5\u00a0months, the patient developed generalized pustular psoriasis. Treatment was therefore started with methotrexate (intravenously, 25\u00a0mg weekly) in combination with fluocortolone (0.5\u00a0mg\/kg body weight\/day). Methotrexate was stopped after 6\u00a0weeks because of a sudden increase in liver transaminases and a lack of efficacy. The patient was subsequently lost to follow\u2010up for more than 6\u00a0months. Until the time of presentation to our outpatient clinic, he had continued topical corticosteroids. He was admitted to our department and therapy with cyclosporine (5\u00a0mg\/kg\/day) was started. After 4\u00a0weeks the condition still remained active and the patient refused further doses of the drug. We therefore started topical therapy with tacrolimus 0.1% ointment (Protopic) twice daily under occlusion. This therapy gave only a slight improvement and was later replaced by mycophenolate mofetil (up to 3\u00a0g\/day) because of failure to improve the patient's symptoms. Response to this treatment was rather limited, even after the addition of cyclosporine. Because of the initial success with acitretin, therapy with acitretin 35\u00a0mg daily was started again. Despite using a lipid\u2010lowering agent, serum lipids again increased rapidly. Further systemic therapies were tried. These included dapsone (200\u00a0mg\/day), cyclosporine (200\u00a0mg\/day) in combination with acitretin (35\u00a0mg\/day), and acitretin in combination with PUVA twice weekly for 9\u00a0weeks. All were unsuccessful. Because of recent publications reporting success in the treatment of ACH with anti\u2010tumor necrosis factor\u2010\u03b1 agents, therapy with etanercept (Enbrel\u00ae, Wyeth) was considered. Purified protein derivative of tuberculin test was performed and found to be negative. Chest X\u2010ray was also normal. Etanercept was initiated at a dose of 25\u00a0mg subcutaneously twice weekly in combination with topical corticosteroids. The response to etanercept therapy has been reported to be dose dependent, and therefore the dose was increased to 50\u00a0mg twice weekly after the second injection. The patient tolerated the therapy without any reactions or adverse effects; his blood count, liver enzyme levels, and renal function remained normal throughout treatment. The patient is now on the 12th week of therapy, but his condition still remains active and has spread proximally (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#f2\">Fig.\u00a02<\/jats:ext-link>).<\/jats:p><jats:p><jats:fig><jats:caption><jats:p>After 12\u00a0weeks of etanercept monotherapy<\/jats:p><\/jats:caption><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" position=\"anchor\" xlink:href=\"urn:x-wiley:00119059:media:IJD3251:IJD_3251_f2\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:fig><\/jats:p>","DOI":"10.1111\/j.1365-4632.2007.03251.x","type":"journal-article","created":{"date-parts":[[2007,11,3]],"date-time":"2007-11-03T11:24:56Z","timestamp":1194089096000},"page":"1205-1207","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lack of efficacy of etanercept in acrodermatitis continua of Hallopeau"],"prefix":"10.1111","volume":"46","author":[{"given":"Esra","family":"Adi\u015fen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"\u00d6zta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"G\u00fcrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,11,2]]},"reference":[{"key":"e_1_2_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.7.925-c"},{"key":"e_1_2_2_3_2","first-page":"106","article-title":"Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of Hallopeau","volume":"70","author":"Piquero\u2010Casals J","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_2_4_2","first-page":"723","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"Christophers E","year":"1999"},{"key":"e_1_2_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2005.01.011"},{"key":"e_1_2_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06893.x"},{"key":"e_1_2_2_7_2","first-page":"360","article-title":"The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of Hallopeau","volume":"4","author":"Kazinski K","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06759.x"},{"key":"e_1_2_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05761.x"},{"key":"e_1_2_2_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000063919"},{"key":"e_1_2_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05719.x"},{"key":"e_1_2_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500430604"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2007.03251.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2007.03251.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T05:45:31Z","timestamp":1696916731000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2007.03251.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1365-4632.2007.03251.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2007.03251.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11]]},"assertion":[{"value":"2007-11-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}